Reports

Drug name	NICE TAs	Comments
Sunitinib capsules	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA) TA169 - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma TA179 - Sunitinib for the treatment of gastrointestinal stromal tumours TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	Hospital use only
SUNITINIB Capsules (generic)		(Off label) Metastatic or unresectable pheochromocytomas and paragangliomas
Supplementary preparations (Addiphos)
Supplementary preparations (Additrace)
Supplementary preparations (Peditrace)
Supplementary preparations (Solivito N)
Supplementary preparations (Vitlipid N)
Suxamethonium injection
Symtuza®
Tacrolimus 0.1% w/w in OrabaseTM		Unlicensed special

University Hospitals Birmingham NHS Foundation Trust